Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
BioMarin price target raised to $120 from $100 at Jefferies » 08:12
11/29/22
11/29
08:12
11/29/22
08:12
BMRN

BioMarin

$98.72 /

+1.85 (+1.91%)

Jefferies analyst Akash…

Jefferies analyst Akash Tewari raised the firm's price target on BioMarin to $120 from $100 and keeps a Buy rating on the shares after having surveyed 25 EU hemophilia A doctors and seeing signals of demand "out of the gate." 80 patients in Germany could get on Roctavian once it is available, which would imply sales above what is modeled by the Street for Q4 of 2022 to Q2 of 2023, said Tewari based on the survey, adding that safety was noted as one of the reasons that some patients may decide to wait first.

ShowHide Related Items >><<
BMRN BioMarin
$98.72 /

+1.85 (+1.91%)

BMRN BioMarin
$98.72 /

+1.85 (+1.91%)

11/25/22 Truist
FDA decision on BioMarin's Roctavian extremely positive, says Truist
11/23/22 Piper Sandler
FDA 'tea leaves' bode well for BioMarin's Roctavian, says Piper Sandler
11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
BMRN BioMarin
$98.72 /

+1.85 (+1.91%)

BMRN BioMarin
$98.72 /

+1.85 (+1.91%)

Over a week ago
On The Fly
Biotech Alert: Searches spiking for these stocks today » 10:29
11/25/22
11/25
10:29
11/25/22
10:29
XOMA

Xoma

$25.00 /

+0.12 (+0.48%)

, VBLT

VBL Therapeutics

/

+

, BMRN

BioMarin

$97.09 /

-0.76 (-0.78%)

, QURE

uniQure

$27.40 /

+1.125 (+4.28%)

, MRTX

Mirati Therapeutics

$98.06 /

+2.24 (+2.34%)

, CSLLY

CSL

$100.10 /

+0.15 (+0.15%)

, OBSV

ObsEva

/

+

These names in the…

ShowHide Related Items >><<
XOMA Xoma
$25.00 /

+0.12 (+0.48%)

VBLT VBL Therapeutics
/

+

QURE uniQure
$27.40 /

+1.125 (+4.28%)

OBSV ObsEva
/

+

MRTX Mirati Therapeutics
$98.06 /

+2.24 (+2.34%)

CSLLY CSL
$100.10 /

+0.15 (+0.15%)

BMRN BioMarin
$97.09 /

-0.76 (-0.78%)

XOMA Xoma
$25.00 /

+0.12 (+0.48%)

VBLT VBL Therapeutics
/

+

07/20/22 Chardan
VBL Therapeutics downgraded to Neutral from Buy at Chardan
07/20/22 H.C. Wainwright
VBL Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
07/20/22 Oppenheimer
VBL Therapeutics downgraded to Perform from Outperform at Oppenheimer
07/18/22 Oppenheimer
VBL Therapeutics assumed with an Outperform at Oppenheimer
BMRN BioMarin
$97.09 /

-0.76 (-0.78%)

11/25/22 Truist
FDA decision on BioMarin's Roctavian extremely positive, says Truist
11/23/22 Piper Sandler
FDA 'tea leaves' bode well for BioMarin's Roctavian, says Piper Sandler
11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
QURE uniQure
$27.40 /

+1.125 (+4.28%)

11/23/22 Truist
uniQure price target raised to $65 from $51 at Truist
08/09/22 Wells Fargo
uniQure price target lowered to $24 from $34 at Wells Fargo
08/09/22 H.C. Wainwright
uniQure selloff brings attractive entry point, says H.C. Wainwright
MRTX Mirati Therapeutics
$98.06 /

+2.24 (+2.34%)

11/22/22 BMO Capital
BMO says Mirati could be valued at up to $200 per share in 'upside scenario'
11/16/22 Citi
Mirati Therapeutics price target lowered to $121 from $127 at Citi
10/28/22 B. Riley
Mirati Therapeutics initiated with a Neutral at B. Riley
10/20/22 Oppenheimer
Revolution Medicines initiated with an Outperform at Oppenheimer
CSLLY CSL
$100.10 /

+0.15 (+0.15%)

11/10/22 Credit Suisse
CSL upgraded to Outperform from Neutral at Credit Suisse
11/03/22 Citi
Arcturus Therapeutics upgraded to Buy at Citi after CSL deal
11/02/22 Barclays
Arcturus Therapeutics upgraded to Equal Weight from Underweight at Barclays
OBSV ObsEva
/

+

08/30/22 H.C. Wainwright
ObsEva downgraded to Neutral from Buy at H.C. Wainwright
07/29/22 Canaccord
ObsEva cut to Hold at Canaccord as company goes 'back to square one'
07/29/22 Canaccord
ObsEva downgraded to Hold from Buy at Canaccord
07/28/22 Cantor Fitzgerald
ObsEva downgraded to Neutral from Overweight at Cantor Fitzgerald
XOMA Xoma
$25.00 /

+0.12 (+0.48%)

VBLT VBL Therapeutics
/

+

QURE uniQure
$27.40 /

+1.125 (+4.28%)

MRTX Mirati Therapeutics
$98.06 /

+2.24 (+2.34%)

BMRN BioMarin
$97.09 /

-0.76 (-0.78%)

MRTX Mirati Therapeutics
$98.06 /

+2.24 (+2.34%)

CSLLY CSL
$100.10 /

+0.15 (+0.15%)

VBLT VBL Therapeutics
/

+

QURE uniQure
$27.40 /

+1.125 (+4.28%)

OBSV ObsEva
/

+

MRTX Mirati Therapeutics
$98.06 /

+2.24 (+2.34%)

CSLLY CSL
$100.10 /

+0.15 (+0.15%)

BMRN BioMarin
$97.09 /

-0.76 (-0.78%)

VBLT VBL Therapeutics
/

+

Recommendations
FDA decision on BioMarin's Roctavian extremely positive, says Truist » 08:17
11/25/22
11/25
08:17
11/25/22
08:17
BMRN

BioMarin

$97.85 /

+6.67 (+7.32%)

Truist analyst Robyn…

Truist analyst Robyn Karnauskas keeps her Buy rating and $133 price target on BioMarin after its disclosure that the FDA will no longer be requiring an AdCom to discuss the BLA review for Roctavian for adults with severe HemA. The news is "very positive" as BioMarin will benefit from first-to-market advantage in the HemA space once Roctavian is approved, the analyst tells investors in a research note.

ShowHide Related Items >><<
BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

11/23/22 Piper Sandler
FDA 'tea leaves' bode well for BioMarin's Roctavian, says Piper Sandler
11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

On The Fly
What You Missed On Wall Street On Wednesday » 16:30
11/23/22
11/23
16:30
11/23/22
16:30
HPQ

HP Inc.

$29.92 /

+0.555 (+1.89%)

, DE

Deere

$437.33 /

+20.63 (+4.95%)

, MANU

Manchester United

$18.80 /

+3.91 (+26.26%)

, AMZN

Amazon.com

$94.17 /

+0.95 (+1.02%)

, COUP

Coupa Software

$58.84 /

+13.16 (+28.81%)

, CS

Credit Suisse

$3.84 /

-0.25 (-6.12%)

, C

Citi

$48.23 /

-1.1 (-2.23%)

, DIS

Disney

$98.95 /

+2.72 (+2.83%)

, JWN

Nordstrom

$21.70 /

-0.96 (-4.24%)

, ADSK

Autodesk

$197.02 /

-11.38 (-5.46%)

, GES

Guess

$20.03 /

+0.29 (+1.47%)

, TSLA

Tesla

$183.26 /

+13.36 (+7.86%)

, MDT

Medtronic

$79.02 /

+1.115 (+1.43%)

, VCTR

Victory Capital

$30.59 /

-1.14 (-3.59%)

, BYND

Beyond Meat

$12.82 /

+0.075 (+0.59%)

, YUM

Yum! Brands

$125.90 /

+1.45 (+1.17%)

, YMM

Full Truck Alliance

$6.95 /

+0.805 (+13.10%)

, CVNA

Carvana

$8.07 /

+1.25 (+18.33%)

, KC

Kingsoft Cloud

$2.76 /

+0.06 (+2.23%)

, MAXR

Maxar Technologies

$23.11 /

-2.88 (-11.08%)

, SATS

EchoStar

$17.51 /

+0.11 (+0.63%)

, WMT

Walmart

$152.42 /

+0.725 (+0.48%)

, AAPL

Apple

$151.08 /

+0.9 (+0.60%)

, VMW

VMware

$119.35 /

+0.96 (+0.81%)

, PAGS

PagSeguro Digital

$10.26 /

-1.755 (-14.61%)

, BMRN

BioMarin

$97.85 /

+6.67 (+7.32%)

Get caught up quickly on…

ShowHide Related Items >><<
YUM Yum! Brands
$125.90 /

+1.45 (+1.17%)

YMM Full Truck Alliance
$6.95 /

+0.805 (+13.10%)

WMT Walmart
$152.42 /

+0.725 (+0.48%)

VMW VMware
$119.35 /

+0.96 (+0.81%)

VCTR Victory Capital
$30.59 /

-1.14 (-3.59%)

TSLA Tesla
$183.26 /

+13.36 (+7.86%)

SATS EchoStar
$17.51 /

+0.11 (+0.63%)

PAGS PagSeguro Digital
$10.26 /

-1.755 (-14.61%)

MDT Medtronic
$79.02 /

+1.115 (+1.43%)

MAXR Maxar Technologies
$23.11 /

-2.88 (-11.08%)

MANU Manchester United
$18.80 /

+3.91 (+26.26%)

KC Kingsoft Cloud
$2.76 /

+0.06 (+2.23%)

JWN Nordstrom
$21.70 /

-0.96 (-4.24%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

GES Guess
$20.03 /

+0.29 (+1.47%)

DIS Disney
$98.95 /

+2.72 (+2.83%)

DE Deere
$437.33 /

+20.63 (+4.95%)

CVNA Carvana
$8.07 /

+1.25 (+18.33%)

CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

C Citi
$48.23 /

-1.1 (-2.23%)

BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

AAPL Apple
$151.08 /

+0.9 (+0.60%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

11/23/22 Evercore ISI
Evercore sticking with In Line rating on HP Inc. as company takes 'right steps'
11/23/22 Citi
HP Inc. restructuring 'unexpected major positive,' says Citi
11/23/22 Barclays
HP Inc. price target lowered to $24 from $27 at Barclays
11/18/22 BofA
HP Inc. price target lowered to $27 from $30 at BofA
DE Deere
$437.33 /

+20.63 (+4.95%)

11/25/22 Morgan Stanley
Deere price target raised to $522 from $424 at Morgan Stanley
11/25/22 Argus
Deere price target raised to $475 from $420 at Argus
11/25/22 JPMorgan
Deere price target raised to $440 from $415 at JPMorgan
11/25/22 UBS
Deere price target raised to $452 from $374 at UBS
MANU Manchester United
$18.80 /

+3.91 (+26.26%)

11/23/22 Jefferies
Jefferies expects 'competitive process' for Manchester United
06/02/22 Deutsche Bank
Manchester United undervalued after selloff, says Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded on 'value disconnect' at Deutsche Bank
03/21/22 Deutsche Bank
Manchester United upgraded to Buy from Hold at Deutsche Bank
AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

11/22/22 Piper Sandler
Amazon.com price target lowered to $119 from $125 at Piper Sandler
11/21/22 JPMorgan
JPMorgan more cautious on online holiday sales, Amazon still top idea
11/18/22 Erste Group
Amazon.com downgraded to Hold from Buy at Erste Group
11/15/22 MoffettNathanson
Amazon.com initiated with an Outperform at MoffettNathanson
COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

11/25/22 Truist
Truist sees 'scarcity value' in Coupa platform, keeps $75 target
11/25/22 BofA
Coupa has strategic value, could also represent attractive PE target, says BofA
11/23/22 Needham
Coupa takeout price would need to be closer to $90, says Needham
11/22/22 DA Davidson
Coupa Software price target lowered to $50 from $70 at DA Davidson
CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

11/07/22 AlphaValue/Baader
Credit Suisse downgraded to Sell from Buy at AlphaValue/Baader
10/28/22 JPMorgan
Credit Suisse price target lowered to CHF 5.50 from CHF 6 at JPMorgan
10/06/22 JPMorgan
Credit Suisse upgraded to Neutral from Underweight at JPMorgan
10/05/22 Societe Generale
Credit Suisse price target lowered to CHF 4.20 from CHF 5.50 at Societe Generale
C Citi
$48.23 /

-1.1 (-2.23%)

11/23/22 Keefe Bruyette
Citi only bank with living will issues, says Keefe Bruyette
11/02/22 JPMorgan
Citi price target raised to $49.50 from $49 at JPMorgan
10/17/22 BMO Capital
Citi price target lowered to $71 from $76 at BMO Capital
10/17/22 Barclays
Citi price target lowered to $57 from $64 at Barclays
DIS Disney
$98.95 /

+2.72 (+2.83%)

11/22/22 Tigress Financial
Disney price target lowered to $177 from $229 at Tigress Financial
11/21/22 JPMorgan
JPMorgan 'reluctant to recommend chasing' Disney shares on rally
11/21/22 Citi
Iger returning 'unalloyed positive' for Disney shares, says Citi
11/21/22 Morgan Stanley
Iger return improves Disney risk/reward, says Morgan Stanley
JWN Nordstrom
$21.70 /

-0.96 (-4.24%)

11/14/22 Deutsche Bank
Nordstrom price target lowered to $22 from $23 at Deutsche Bank
09/16/22 Jefferies
Liverpool buying stake 'vote of confidence' in Nordstrom, says Jefferies
09/15/22 Jefferies
Nordstrom assumed with Buy from Hold at Jefferies
08/25/22 Barclays
Nordstrom price target lowered to $18 from $21 at Barclays
ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

11/23/22 RBC Capital
Autodesk price target lowered to $225 from $260 at RBC Capital
11/23/22 Deutsche Bank
Autodesk price target lowered to $225 from $255 at Deutsche Bank
11/23/22 Stifel
Autodesk price target lowered to $220 from $270 at Stifel
11/23/22 Baird
Autodesk price target lowered to $244 from $255 at Baird
GES Guess
$20.03 /

+0.29 (+1.47%)

05/26/22 B. Riley
Guess price target lowered to $29 from $36 at B. Riley
03/17/22 B. Riley
Guess price target lowered to $36 from $38 at B. Riley
11/30/21 Jefferies
Guess assumed with a Buy at Jefferies
TSLA Tesla
$183.26 /

+13.36 (+7.86%)

11/23/22 Morgan Stanley
Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff
11/23/22 Citi
Tesla upgraded to Neutral from Sell at Citi
11/10/22 Wedbush
Tesla removed from 'Best Ideas' list at Wedbush
11/02/22 Bernstein
Bernstein analysis shows Tesla total software run rate revenues of $290M/quarter
MDT Medtronic
$79.02 /

+1.115 (+1.43%)

11/25/22 Barclays
Medtronic price target lowered to $85 from $90 at Barclays
11/23/22 RBC Capital
Medtronic price target lowered to $102 from $110 at RBC Capital
11/23/22 Morgan Stanley
Medtronic price target lowered to $88 from $97 at Morgan Stanley
11/23/22 Deutsche Bank
Medtronic price target lowered to $80 from $85 at Deutsche Bank
VCTR Victory Capital
$30.59 /

-1.14 (-3.59%)

11/23/22 Piper Sandler
Victory Capital downgraded to Underweight from Overweight at Piper Sandler
11/11/22 B. Riley
Victory Capital price target raised to $40 from $36 at B. Riley
08/08/22 Oppenheimer
Victory Capital assumed with a Perform at Oppenheimer
07/15/22 Piper Sandler
Victory Capital price target lowered to $33 from $35 at Piper Sandler
BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

11/23/22 Goldman Sachs
Beyond Meat price target lowered to $5 from $14 at Goldman Sachs
11/10/22 Bernstein
Beyond Meat price target lowered to $10 from $22 at Bernstein
11/10/22 Mizuho
Beyond Meat price target lowered to $11 from $27 at Mizuho
10/17/22 Canaccord
Beyond Meat price target lowered to $14 from $15 at Canaccord
YUM Yum! Brands
$125.90 /

+1.45 (+1.17%)

11/23/22 Argus
Argus upgrades Yum! Brands to Buy, sees 'solid' growth pace from value menu
11/23/22 Argus
Yum! Brands upgraded to Buy from Hold at Argus
10/19/22 Cowen
Yum! Brands price target lowered to $130 from $143 at Cowen
09/07/22 Bernstein
Bernstein starts Yum! Brands at Outperform with $144 price target
YMM Full Truck Alliance
$6.95 /

+0.805 (+13.10%)

06/29/22 Credit Suisse
Full Truck Alliance initiated with an Outperform at Credit Suisse
06/09/22 Citi
Full Truck Alliance price target lowered to $13 from $15 at Citi
03/02/22 Citi
Full Truck Alliance price target lowered to $15 from $16.50 at Citi
CVNA Carvana
$8.07 /

+1.25 (+18.33%)

11/22/22 Baird
Carvana downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Carvana downgraded to Market Perform from Outperform at Cowen
11/21/22 Argus
Carvana downgraded to Sell from Hold at Argus
11/21/22 Argus
Carvana downgraded to Sell from Hold at Argus
KC Kingsoft Cloud
$2.76 /

+0.06 (+2.23%)

09/07/22 Citi
Kingsoft Cloud downgraded to Neutral from Buy at Citi
06/09/22 Citi
Kingsoft Cloud price target lowered to $8.50 from $10 at Citi
04/10/22 Goldman Sachs
Kingsoft Cloud assumed with a Neutral at Goldman Sachs
03/25/22 CLSA
Kingsoft Cloud downgraded to Outperform from Buy at CLSA
MAXR Maxar Technologies
$23.11 /

-2.88 (-11.08%)

11/23/22 Truist
Maxar Technologies price target lowered to $37 from $44 at Truist
11/07/22 BMO Capital
Maxar Technologies price target lowered to $27 from $32 at BMO Capital
11/04/22 Canaccord
Maxar Technologies price target lowered to $38 from $40 at Canaccord
08/10/22 Truist
Maxar Technologies price target lowered to $44 from $52 at Truist
SATS EchoStar
$17.51 /

+0.11 (+0.63%)

11/04/22 Raymond James
EchoStar downgraded to Outperform from Strong Buy at Raymond James
11/04/22 Raymond James
EchoStar downgraded to Outperform from Strong Buy at Raymond James
07/22/22 Raymond James
EchoStar removed from Analyst Current Favorites list at Raymond James
05/24/22 William Blair
Gogo pact with Echostar doubles addressable market, says William Blair
WMT Walmart
$152.42 /

+0.725 (+0.48%)

11/18/22 Gordon Haskett
Ross Stores upgraded to Buy at Gordon Haskett as off-price starts to turn corner
11/17/22 Truist
Target price target lowered to $151 from $165 at Truist
11/17/22 Morgan Stanley
Walmart price target raised to $164 from $150 at Morgan Stanley
11/17/22 Oppenheimer
Oppenheimer 'cautiously optimistic' about Walmart upcoming holiday season
AAPL Apple
$151.08 /

+0.9 (+0.60%)

11/23/22 Wedbush
iPhone demand into Black Friday may put Apple in 'major shortage,' says Wedbush
11/22/22 Canaccord
Apple iPhone demand remains strong, supply could be issue, says Canaccord
11/21/22 JPMorgan
Apple likely past trough for iPhone Pro supply, says JPMorgan
11/21/22 Craig-Hallum
Craig-Hallum bullish on Globalstar amid upcoming Apple support for Band 53
VMW VMware
$119.35 /

+0.96 (+0.81%)

11/15/22 Mizuho
VMware price target lowered to $135 from $138 at Mizuho
10/17/22 Needham
Nutanix price target raised to $31 from $25 at Needham
10/17/22 Northland
Salesforce initiated with a Market Perform at Northland
07/06/22 Raymond James
VMware downgraded to Market Perform from Outperform at Raymond James
PAGS PagSeguro Digital
$10.26 /

-1.755 (-14.61%)

11/23/22 Evercore ISI
PagSeguro Digital price target lowered to $13 from $16 at Evercore ISI
11/23/22 Susquehanna
PagSeguro Digital results largely inline with expectations, says Susquehanna
11/23/22 Cantor Fitzgerald
PagSeguro Digital price target lowered to $20 from $25 at Cantor Fitzgerald
11/21/22 Deutsche Bank
PagSeguro Digital price target lowered to $20 from $25 at Deutsche Bank
BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

11/25/22 Truist
FDA decision on BioMarin's Roctavian extremely positive, says Truist
11/23/22 Piper Sandler
FDA 'tea leaves' bode well for BioMarin's Roctavian, says Piper Sandler
11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
YUM Yum! Brands
$125.90 /

+1.45 (+1.17%)

YMM Full Truck Alliance
$6.95 /

+0.805 (+13.10%)

WMT Walmart
$152.42 /

+0.725 (+0.48%)

VMW VMware
$119.35 /

+0.96 (+0.81%)

VCTR Victory Capital
$30.59 /

-1.14 (-3.59%)

TSLA Tesla
$183.26 /

+13.36 (+7.86%)

PAGS PagSeguro Digital
$10.26 /

-1.755 (-14.61%)

MDT Medtronic
$79.02 /

+1.115 (+1.43%)

MAXR Maxar Technologies
$23.11 /

-2.88 (-11.08%)

MANU Manchester United
$18.80 /

+3.91 (+26.26%)

KC Kingsoft Cloud
$2.76 /

+0.06 (+2.23%)

JWN Nordstrom
$21.70 /

-0.96 (-4.24%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

GES Guess
$20.03 /

+0.29 (+1.47%)

DIS Disney
$98.95 /

+2.72 (+2.83%)

DE Deere
$437.33 /

+20.63 (+4.95%)

CVNA Carvana
$8.07 /

+1.25 (+18.33%)

CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

C Citi
$48.23 /

-1.1 (-2.23%)

BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

AAPL Apple
$151.08 /

+0.9 (+0.60%)

  • 22
    Apr
YUM Yum! Brands
$125.90 /

+1.45 (+1.17%)

YMM Full Truck Alliance
$6.95 /

+0.805 (+13.10%)

WMT Walmart
$152.42 /

+0.725 (+0.48%)

VMW VMware
$119.35 /

+0.96 (+0.81%)

TSLA Tesla
$183.26 /

+13.36 (+7.86%)

MANU Manchester United
$18.80 /

+3.91 (+26.26%)

KC Kingsoft Cloud
$2.76 /

+0.06 (+2.23%)

JWN Nordstrom
$21.70 /

-0.96 (-4.24%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

DIS Disney
$98.95 /

+2.72 (+2.83%)

DE Deere
$437.33 /

+20.63 (+4.95%)

CVNA Carvana
$8.07 /

+1.25 (+18.33%)

CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

C Citi
$48.23 /

-1.1 (-2.23%)

BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

AAPL Apple
$151.08 /

+0.9 (+0.60%)

YUM Yum! Brands
$125.90 /

+1.45 (+1.17%)

YMM Full Truck Alliance
$6.95 /

+0.805 (+13.10%)

WMT Walmart
$152.42 /

+0.725 (+0.48%)

VMW VMware
$119.35 /

+0.96 (+0.81%)

TSLA Tesla
$183.26 /

+13.36 (+7.86%)

PAGS PagSeguro Digital
$10.26 /

-1.755 (-14.61%)

MAXR Maxar Technologies
$23.11 /

-2.88 (-11.08%)

KC Kingsoft Cloud
$2.76 /

+0.06 (+2.23%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

GES Guess
$20.03 /

+0.29 (+1.47%)

DIS Disney
$98.95 /

+2.72 (+2.83%)

DE Deere
$437.33 /

+20.63 (+4.95%)

CVNA Carvana
$8.07 /

+1.25 (+18.33%)

CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

C Citi
$48.23 /

-1.1 (-2.23%)

BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

BMRN BioMarin
$97.85 /

+6.67 (+7.32%)

AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

AAPL Apple
$151.08 /

+0.9 (+0.60%)

WMT Walmart
$152.42 /

+0.725 (+0.48%)

VMW VMware
$119.35 /

+0.96 (+0.81%)

TSLA Tesla
$183.26 /

+13.36 (+7.86%)

PAGS PagSeguro Digital
$10.26 /

-1.755 (-14.61%)

MDT Medtronic
$79.02 /

+1.115 (+1.43%)

MANU Manchester United
$18.80 /

+3.91 (+26.26%)

JWN Nordstrom
$21.70 /

-0.96 (-4.24%)

HPQ HP Inc.
$29.92 /

+0.555 (+1.89%)

GES Guess
$20.03 /

+0.29 (+1.47%)

DIS Disney
$98.95 /

+2.72 (+2.83%)

DE Deere
$437.33 /

+20.63 (+4.95%)

CVNA Carvana
$8.07 /

+1.25 (+18.33%)

CS Credit Suisse
$3.84 /

-0.25 (-6.12%)

COUP Coupa Software
$58.84 /

+13.16 (+28.81%)

C Citi
$48.23 /

-1.1 (-2.23%)

BYND Beyond Meat
$12.82 /

+0.075 (+0.59%)

AMZN Amazon.com
$94.17 /

+0.95 (+1.02%)

ADSK Autodesk
$197.02 /

-11.38 (-5.46%)

Recommendations
FDA 'tea leaves' bode well for BioMarin's Roctavian, says Piper Sandler » 10:32
11/23/22
11/23
10:32
11/23/22
10:32
BMRN

BioMarin

$98.35 /

+7.17 (+7.86%)

, QURE

uniQure

$24.22 /

+1.23 (+5.35%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond cautions that "reading FDA tea leaves can be a dangerous game," but with that said he thinks it is "reasonable to connect a couple of recent data points from FDA" that he thinks bode well for Roctavian's U.S. approval process, including yesterday's approval of uniQure's (QURE) hemophilia B gene therapy Hemgenix and today's announcement that the FDA no longer intends to conduct an AdCom to review BioMarin's (BMRN) Roctavian hemophilia A application. The analyst, who reminds investors that Roctavian's EU launch is currently underway and that his recent hematologist survey makes it appear there is "some degree of pent-up demand for the therapy," has an Overweight rating and $128 price target on BioMarin shares.

ShowHide Related Items >><<
QURE uniQure
$24.22 /

+1.23 (+5.35%)

BMRN BioMarin
$98.35 /

+7.17 (+7.86%)

BMRN BioMarin
$98.35 /

+7.17 (+7.86%)

11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
QURE uniQure
$24.22 /

+1.23 (+5.35%)

11/23/22 Truist
uniQure price target raised to $65 from $51 at Truist
08/09/22 Wells Fargo
uniQure price target lowered to $24 from $34 at Wells Fargo
08/09/22 H.C. Wainwright
uniQure selloff brings attractive entry point, says H.C. Wainwright
08/08/22 Chardan
uniQure price target lowered to $60 from $65 at Chardan
QURE uniQure
$24.22 /

+1.23 (+5.35%)

BMRN BioMarin
$98.35 /

+7.17 (+7.86%)

QURE uniQure
$24.22 /

+1.23 (+5.35%)

BMRN BioMarin
$98.35 /

+7.17 (+7.86%)

Hot Stocks
BioMarin up 6% to $96.39 after FDA won't hold meeting on BLA for ROCTAVIAN  08:59
11/23/22
11/23
08:59
11/23/22
08:59
BMRN

BioMarin

$91.21 /

+2.705 (+3.06%)

 
ShowHide Related Items >><<
BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

Hot Stocks
BioMarin: FDA does not plan to hold meeting to discuss BLA for ROCTAVIAN » 08:31
11/23/22
11/23
08:31
11/23/22
08:31
BMRN

BioMarin

$91.21 /

+2.705 (+3.06%)

BioMarin Pharmaceutical…

BioMarin Pharmaceutical announced advancements in the U.S. FDA review of the Biologics License Application of ROCTAVIAN for adults with severe hemophilia A. The company was recently notified by the FDA that after further consideration, at this time, the Agency no longer plans to hold an advisory committee meeting to discuss the BLA for ROCTAVIAN that is currently under review. Previously, the FDA communicated to the company that it did intend to hold an advisory committee meeting but did not specify a date. The company also remains on track to host the scheduled FDA Pre-Licensure Inspection of BioMarin's gene therapy manufacturing facility located in Novato, CA.

ShowHide Related Items >><<
BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

11/23/22 Morgan Stanley
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

Recommendations
Approval of CSL's Hemgenix positive for BioMarin, says Morgan Stanley » 08:23
11/23/22
11/23
08:23
11/23/22
08:23
BMRN

BioMarin

$91.21 /

+2.705 (+3.06%)

, CSLLY

CSL

$99.95 /

+1.55 (+1.58%)

After CSL (CSLLY)…

After CSL (CSLLY) announced the FDA approved Hemgenix for the treatment of adults with Hemophilia B with a "clean" label with no black box warning or restrictions on certain patient groups, Morgan Stanley analyst Matthew Harrison said he views the approval as "a clear sentiment positive" for BioMarin given investor concern around FDA approvals of gene therapy products and potential risks related to Roctavian. The analyst, who expects the Hemgenix news to drive BioMarin higher, has an Overweight rating and $113 price target on BioMarin shares.

ShowHide Related Items >><<
CSLLY CSL
$99.95 /

+1.55 (+1.58%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
CSLLY CSL
$99.95 /

+1.55 (+1.58%)

11/10/22 Credit Suisse
CSL upgraded to Outperform from Neutral at Credit Suisse
11/03/22 Citi
Arcturus Therapeutics upgraded to Buy at Citi after CSL deal
11/02/22 Barclays
Arcturus Therapeutics upgraded to Equal Weight from Underweight at Barclays
09/23/22 Jefferies
CSL upgraded to Buy from Hold at Jefferies
BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

CSLLY CSL
$99.95 /

+1.55 (+1.58%)

CSLLY CSL
$99.95 /

+1.55 (+1.58%)

BMRN BioMarin
$91.21 /

+2.705 (+3.06%)

Conference/Events
JPMorgan large/smid cap biotech analysts hold analyst/industry conference call » 14:45
11/22/22
11/22
14:45
11/22/22
14:45
ASND

Ascendis Pharma

$117.99 /

+0.79 (+0.67%)

, BMRN

BioMarin

$88.63 /

+0.125 (+0.14%)

, BBIO

BridgeBio

$8.35 /

-0.44 (-5.01%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Fye and SMid Cap Biotech Analyst Rama discuss Ascendis Pharma/BioMarin Pharmaceuticals/BridgeBio Pharma current and future Achondroplasia treatment on an Analyst/Industry conference call to be held on November 22 at 3 pm. Webcast Link

ShowHide Related Items >><<
BMRN BioMarin
$88.63 /

+0.125 (+0.14%)

BBIO BridgeBio
$8.35 /

-0.44 (-5.01%)

ASND Ascendis Pharma
$117.99 /

+0.79 (+0.67%)

ASND Ascendis Pharma
$117.99 /

+0.79 (+0.67%)

11/15/22 Citi
Ascendis Pharma selloff yesterday a buying opportunity, says Citi
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Wedbush
Ascendis Pharma price target raised to $164 from $151 at Wedbush
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
BMRN BioMarin
$88.63 /

+0.125 (+0.14%)

10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
BBIO BridgeBio
$8.35 /

-0.44 (-5.01%)

08/24/22 Mizuho
BridgeBio price target lowered to $23 from $25 at Mizuho
08/05/22 JPMorgan
BridgeBio selloff on Alnylam readout overdone, says JPMorgan
07/26/22 Piper Sandler
BioMarin competitor BridgeBio data falls short, says Piper Sandler
03/16/22 H.C. Wainwright
BridgeBio price target lowered to $22 from $24 at H.C. Wainwright
BMRN BioMarin
$88.63 /

+0.125 (+0.14%)

BBIO BridgeBio
$8.35 /

-0.44 (-5.01%)

ASND Ascendis Pharma
$117.99 /

+0.79 (+0.67%)

BMRN BioMarin
$88.63 /

+0.125 (+0.14%)

ASND Ascendis Pharma
$117.99 /

+0.79 (+0.67%)

Conference/Events
JPMorgan large/smid cap biotech analysts hold analyst/industry conference call » 10:45
11/22/22
11/22
10:45
11/22/22
10:45
ASND

Ascendis Pharma

$118.15 /

+0.95 (+0.81%)

, BMRN

BioMarin

$88.61 /

+0.105 (+0.12%)

, BBIO

BridgeBio

$8.73 /

-0.06 (-0.68%)

Large Cap Biotech Analyst…

Large Cap Biotech Analyst Fye and SMid Cap Biotech Analyst Rama discuss Ascendis Pharma/BioMarin Pharmaceuticals/BridgeBio Pharma current and future Achondroplasia treatment on an Analyst/Industry conference call to be held on November 22 at 3 pm. Webcast Link

ShowHide Related Items >><<
BMRN BioMarin
$88.61 /

+0.105 (+0.12%)

BBIO BridgeBio
$8.73 /

-0.06 (-0.68%)

ASND Ascendis Pharma
$118.15 /

+0.95 (+0.81%)

ASND Ascendis Pharma
$118.15 /

+0.95 (+0.81%)

11/15/22 Citi
Ascendis Pharma selloff yesterday a buying opportunity, says Citi
11/14/22 Morgan Stanley
BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
11/14/22 Wedbush
Ascendis Pharma price target raised to $164 from $151 at Wedbush
11/14/22 Piper Sandler
BioMarin should rally 'meaningfully' after Ascendis data, says Piper Sandler
BMRN BioMarin
$88.61 /

+0.105 (+0.12%)

10/31/22 Oppenheimer
BioMarin upgraded to Outperform from Perform at Oppenheimer
10/26/22 Piper Sandler
Handwringing over BioMarin's Roctavian misplaced, says Piper Sandler
BBIO BridgeBio
$8.73 /

-0.06 (-0.68%)

08/24/22 Mizuho
BridgeBio price target lowered to $23 from $25 at Mizuho
08/05/22 JPMorgan
BridgeBio selloff on Alnylam readout overdone, says JPMorgan
07/26/22 Piper Sandler
BioMarin competitor BridgeBio data falls short, says Piper Sandler
03/16/22 H.C. Wainwright
BridgeBio price target lowered to $22 from $24 at H.C. Wainwright
BMRN BioMarin
$88.61 /

+0.105 (+0.12%)

BBIO BridgeBio
$8.73 /

-0.06 (-0.68%)

ASND Ascendis Pharma
$118.15 /

+0.95 (+0.81%)

BMRN BioMarin
$88.61 /

+0.105 (+0.12%)

ASND Ascendis Pharma
$118.15 /

+0.95 (+0.81%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.